X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA PIRAMAL ENTERPRISES NATCO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 13.2 7.7 170.7% View Chart
P/BV x 3.8 1.4 272.7% View Chart
Dividend Yield % 1.2 1.2 100.2%  

Financials

 NATCO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
PIRAMAL ENTERPRISES
Mar-18
NATCO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,0803,083 35.0%   
Low Rs6711,902 35.3%   
Sales per share (Unadj.) Rs592.1589.7 100.4%  
Earnings per share (Unadj.) Rs188.4284.0 66.3%  
Cash flow per share (Unadj.) Rs206.3310.5 66.5%  
Dividends per share (Unadj.) Rs8.2525.00 33.0%  
Dividend yield (eoy) %0.91.0 93.9%  
Book value per share (Unadj.) Rs833.61,467.0 56.8%  
Shares outstanding (eoy) m36.90180.27 20.5%   
Bonus/Rights/Conversions ISIS-  
Price / Sales ratio x1.54.2 35.0%   
Avg P/E ratio x4.68.8 53.0%  
P/CF ratio (eoy) x4.28.0 52.9%  
Price / Book Value ratio x1.11.7 61.8%  
Dividend payout %4.48.8 49.8%   
Avg Mkt Cap Rs m32,311449,332 7.2%   
No. of employees `0004.86.8 70.6%   
Total wages/salary Rs m3,25619,881 16.4%   
Avg. sales/employee Rs Th4,522.515,535.6 29.1%   
Avg. wages/employee Rs Th674.02,905.4 23.2%   
Avg. net profit/employee Rs Th1,439.07,482.5 19.2%   
INCOME DATA
Net Sales Rs m21,848106,310 20.6%  
Other income Rs m4042,595 15.6%   
Total revenues Rs m22,252108,906 20.4%   
Gross profit Rs m9,28451,599 18.0%  
Depreciation Rs m6624,773 13.9%   
Interest Rs m15429,783 0.5%   
Profit before tax Rs m8,87219,638 45.2%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,920-28,764 -6.7%   
Profit after tax Rs m6,95251,203 13.6%  
Gross profit margin %42.548.5 87.6%  
Effective tax rate %21.6-146.5 -14.8%   
Net profit margin %31.848.2 66.1%  
BALANCE SHEET DATA
Current assets Rs m21,307118,154 18.0%   
Current liabilities Rs m5,920462,260 1.3%   
Net working cap to sales %70.4-323.7 -21.8%  
Current ratio x3.60.3 1,408.1%  
Inventory Days Days7327 275.6%  
Debtors Days Days10747 228.9%  
Net fixed assets Rs m14,986113,727 13.2%   
Share capital Rs m369361 102.4%   
"Free" reserves Rs m30,353264,093 11.5%   
Net worth Rs m30,760264,454 11.6%   
Long term debt Rs m0242,206 0.0%   
Total assets Rs m37,151726,834 5.1%  
Interest coverage x58.61.7 3,532.1%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.60.1 402.1%   
Return on assets %19.111.1 171.7%  
Return on equity %22.619.4 116.7%  
Return on capital %29.310.3 284.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32215,110 68.3%   
Fx outflow Rs m2,9784,298 69.3%   
Net fx Rs m7,34310,813 67.9%   
CASH FLOW
From Operations Rs m4,636-159,666 -2.9%  
From Investments Rs m-11,155-17,677 63.1%  
From Financial Activity Rs m6,509186,503 3.5%  
Net Cashflow Rs m-189,364 -0.2%  

Share Holding

Indian Promoters % 52.0 52.9 98.4%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 4.0 196.0%  
FIIs % 16.6 26.6 62.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 16.5 157.6%  
Shareholders   25,395 93,274 27.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  MERCK LTD  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Flat; Bharti Airtel & Yes Bank Top Gainers(12:30 pm)

Share markets in India are presently trading on a flat note. Sectoral indices are trading mixed with stocks in the oil & gas sector.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Dec 14, 2018 03:35 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - MERCK LTD COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS